Cannabis
Commented by Stefan Feulner on March 4th, 2021 | 09:16 CET
NanoRepro, EXMceuticals, Deutsche Telekom - The profiteers of the new world!
The world has changed since last year. The goal is to fight and contain the virus, which has destroyed our everyday life. In addition to the vaccine manufacturers such as BioNTech, AstraZeneca or Moderna, there are more and more new winners emerging from nowhere to become new stock market stars. Currently, the dominant topic, apart from the vaccination programs that are still hardly taking place in Germany, is the "national testing strategy." At the very least, this should enable a more regular and open life. Be there!
ReadCommented by André Will-Laudien on December 7th, 2020 | 10:01 CET
EXMceuticals, Aurora, Xphyto Therapeutics - Cannabis 2.0 and Psilocybin!
The North American Cannabis Index has brought itself back to life in October! The index lost 80% since the beginning of 2019, but it's going up again with the survivors of the industry. Overall, the capitalization of the sector has decreased by 85%, with the election of Joe Biden, the second buying wave of purchases is underway. If hemp production was the initial focus, it is now the applications, the achieved market access and new active ingredient combinations. In the slipstream of the therapeutic plant customer, another topic came to the fore that has caused investors' hearts to stutter in recent weeks: the psychedelic drugs in the form of psilocybin. Psilocybin has been used as an entheogen and hallucinogenic drug since prehistoric times. Now the medical applications are being investigated. The trend is already running at full speed, the Canadian brokerage house Canaccord estimates the market volume of all indications that are suitable for treatment with active psychedelic ingredients to be USD 100 billion.
ReadCommented by Mario Hose on July 15th, 2020 | 12:23 CEST
BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential
In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can be different. The development of corona vaccines and antibody tests will make a lot of money in the future and the legalization of cannabis in the USA on a federal level has the potential to create a renaissance.
ReadCommented by Mario Hose on May 19th, 2020 | 15:02 CEST
Aphria, Aurora Cannabis, Canopy Growth, EXMceuticals - do not miss the entry!
The nationwide and anonymous advertising format of Deutsche Post is called POSTAKTUELL and is published regularly in large print runs. The stack of advertising is wrapped in a foil and the practical added value for the recipient is the TV guide. The front of POSTAKTUELL is particularly eye-catching and anyone who advertises there will reach a lot of people. In the meantime, advertising for products and applications with active ingredients from the cannabis plant is already being done there. CBD reaches the general public and despite the Corona Pandemic, the industry's stocks are running in turnaround mode and have left the lows.
ReadCommented by Mario Hose on March 23rd, 2020 | 15:00 CET
Aurora Cannabis, Bayer, EXMceuticals - ready for the time after Corona
The cannabis hype was over and then came the corona crisis. Investors who believed in the active ingredient of cannabis and put money into the shares of companies in this industry are now likely to be sitting on a huge loss in most cases. It all started with the idea of a few companies to make one of the oldest medicinal plants in the world acceptable for general use within the framework of legalization. However, high margins and a large market soon led to competition and a brokerage industry was earning a lot of money - soon several hundred cannabis companies were listed on the stock exchange.
ReadCommented by Mario Hose on February 25th, 2020 | 13:38 CET
Aurora Cannabis, Canopy Growth, EXMceuticals - who will be the best turnaround story?
Cannabis shares are not in demand at the moment. About a year ago the growth potential and possibilities of the rediscovered historical medicinal plant seemed to be endless. Today it is different, there is a hangover mood. The hype back then led to a buyer's market. Investors underbid each other with purchase orders and shareholders surrendered their shares in a nervous mood in order to set off for new shores. This or something similar may be the current situation in the environment of numerous cannabis companies. But experienced investors also know that consolidation phases are the foundation for success stories.
ReadCommented by Mario Hose on February 11th, 2020 | 14:55 CET
Aphria, Canopy Growth, EXMceuticals - Europe becomes the largest cannabis market
The consulting firm Prohibition Partners expects Europe to grow into the world's largest market for legal cannabis products in the next five years. Germany will become by far the largest market for medical cannabis products. According to the experts, Europe will thus overtake the North American market.
ReadCommented by Mario Hose on February 4th, 2020 | 05:50 CET
Aurora Cannabis, EXMceuticals, Tilray - Cannabis development in Portugal
From the street to the clinic. Cannabis had the image of an illegal street drug in most rich countries since the prohibition in the USA in the 1930s. Although cannabis has been used as a medicinal plant for more than 1,000 years, the past decades have been marked by other pharmaceutical products. The market and attitudes towards cannabis are now changing. Doctors, patients, companies and investors see opportunities to profit from this development.
ReadCommented by Mario Hose on January 21st, 2020 | 13:48 CET
Aphria, Cronos Group, EXMceuticals - it is a buyers' market!
The shares of numerous well-known and unknown cannabis companies have had a dramatic year 2019. Price losses of over 50% are not uncommon. What costs only half today may have become twice as attractive. Due to the large number of cannabis companies listed on the stock exchange, this is the time for investors who are planning a new investment.
ReadCommented by Mario Hose on January 16th, 2020 | 11:53 CET
Aurora Cannabis, Canopy Growth, EXMceuticals - Profits with turnaround
2019 was not a good year for investors in the cannabis sector with a long-term approach. After a never-ending rally in the years before, the party was over. However, the price capers can also be an opportunity to enter companies that are now one experience richer than they were a year ago in a champagne mood.
Read